ESR1 and breast carcinoma: In summary, the head-to-head comparisons described here of PR isoforms, PR agonists and antagonists and their intersection with estrogen signaling strongly suggest a need for follow up studies to identify and develop appropriate biomarkers to select breast cancer patients that will benefit from ER/PR-targeted co-therapies.